A202 TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 5.4 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

BACKGROUND: Tofacitinib is an oral, small molecule JAK inhibitor approved in several countries for the treatment of ulcerative colitis (UC). Efficacy and safety of tofacitinib as UC induction and maintenance therapy were evaluated in Phase (P)2(1) and P3(2) randomized, placebo-controlled studies, an...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Can Assoc Gastroenterol
Main Authors: Sandborn, W J, Panés, J, Panaccione, R, D’Haens, G, Sands, B E, Su, C, Moscariello, M, Jones, T V, Pedersen, R D, Friedman, G S, Lawendy, N, Chan, G
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Posters Of Distinction
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512642/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.201
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki